Your browser doesn't support javascript.
loading
Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation.
Salas, Maria Queralt; Atenafu, Eshetu G; Bautista, Maria Rhida; Prem, Shruti; Lam, Wilson; Datt Law, Arjun; Shaibani, Zeyad-Al; Kim, Dennis Dong Hwan; Michelis, Fotios V; Lipton, Jeffrey Howard; Viswabandya, Auro; Mattsson, Jonas; Kumar, Rajat.
Afiliación
  • Salas MQ; Section of Medical Oncology and Hematology, Department of Internal Medicine, University of Toronto, ON, Canada.
  • Atenafu EG; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bautista MR; Department of Biostatistics, Princes Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Prem S; Section of Medical Oncology and Hematology, Department of Internal Medicine, University of Toronto, ON, Canada.
  • Lam W; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Datt Law A; Section of Medical Oncology and Hematology, Department of Internal Medicine, University of Toronto, ON, Canada.
  • Shaibani ZA; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kim DDH; Section of Medical Oncology and Hematology, Department of Internal Medicine, University of Toronto, ON, Canada.
  • Michelis FV; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Lipton JH; Section of Medical Oncology and Hematology, Department of Internal Medicine, University of Toronto, ON, Canada.
  • Viswabandya A; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Mattsson J; Section of Medical Oncology and Hematology, Department of Internal Medicine, University of Toronto, ON, Canada.
  • Kumar R; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Eur J Haematol ; 104(1): 36-45, 2020 Jan.
Article en En | MEDLINE | ID: mdl-31549435
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Antígenos CD34 / Neoplasias Hematológicas / Acondicionamiento Pretrasplante / Ciclofosfamida Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Antígenos CD34 / Neoplasias Hematológicas / Acondicionamiento Pretrasplante / Ciclofosfamida Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido